Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors

By  

Medical Oncology, Vol. 24, Iss. 2, 2007-06 ,pp. : 189-196

Humana Press, Inc

Access to resources Recommend Favorite

Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2

By Rubenstein Marvin   Tsui Paulus   Guinan Patrick  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 592-599

Humana Press, Inc

Access to resources Recommend Favorite

Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR

By Rubenstein Marvin  

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1212-1218

Humana Press, Inc

Access to resources Recommend Favorite

Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model

By Tsui Paulus   Rubenstein Marvin   Guinan Patrick  

Medical Oncology, Vol. 21, Iss. 4, 2004-12 ,pp. : 339-348

Humana Press, Inc

Access to resources Recommend Favorite

Bcl-2/bcl-xL Bispecific Antisense Treatment Sensitizes Breast Carcinoma Cells to Doxorubicin, Paclitaxel and Cyclophosphamide

By Simões-Wüst A.P.  

Breast Cancer Research and Treatment, Vol. 76, Iss. 2, 2002-11 ,pp. : 157-166

Springer Publishing Company

Access to resources Recommend Favorite